Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 3/20 | 0.36 |
| ▸ | RBP4 | P02753 | 3/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL342330 | 1.00 | KDR (0.40) | KDRKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL342884 | 0.95 | KDR (0.43) | KDRKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL342883 | 0.95 | KDR (0.43) | KDRKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL342882 | 0.95 | KDR (0.43) | KDRKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL342331 | 0.89 | KDR (0.38) | KDRSYKRBP4 | |
| Trifluoroacetic Acid SCHEMBL342780 | 0.89 | HSD17B10 (0.38) | KDM4EMEN1ALDH1A1KMT2AHSD17B10 | |
| Trifluoroacetic Acid SCHEMBL342782 | 0.89 | HSD17B10 (0.38) | KDM4EMEN1ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL343079 | 0.88 | KDR (0.42) | KDRHSD17B10 | |
| SCHEMBL343078 | 0.88 | KDR (0.42) | KDRHSD17B10 | |
| SCHEMBL343077 | 0.88 | KDR (0.42) | KDRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367690-B2 | Aminopyridine derivatives having aurora a selective inhibitory action | VERTEX PHARMACEUTICALS INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120015969-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICALS CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015969-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | AURKA, AURKC, AURKB | KDR 982/4885KDM4E 621/4885MEN1 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.